Manuscripts

Search by keyword or author name.

Showing 1453 manuscripts.

IMPAACT 2016: Operationalizing HIV Intervention Adaptations to Inform the Science and Outcomes of
Implementation

Jennifer Libous, Nicole A. MontaƱez, Geri R. Donenberg, Dorothy E. Dow, Suad Kapetanovic, Janice Buckley, Tebogo Jacqueline Kakhu, Portia Kamthunzi, Limbika A. Maliwichi, Tichaona Vhembo, Tariro Dianah Chawana, Teacler Nematadzira. IMPAACT 2016: Operationalizing HIV Intervention Adaptations to Inform the Science and Outcomes of Implementation. Frontiers in Reproductive Health. 2021. 3

Journal

Frontiers in Reproductive Health

Study

IMPAACT 2016

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

Shahin Lockman, Sean Brummel, Lauren Ziemba, Lynda Stranix-Chibanda, Katie McCarthy, Patrick Jean-Philippe, Benjamin Johnston, Chelsea Krotje, Lee Fairlie, Risa Hoffman, Paul E. Sax, Sikhulile Moyo, Nahida Chakhtoura, Jeffrey S. A. Stringer, Gaerolwe Masheto, Violet Korutaro, Haseena Cassim, Blandina Mmbaga, Esau Joao, Sherika Hanley, Lynette Purdue, Lewis Ball Holmes, Jeremiah D. Momper, Roger L. Shapiro, Navdeep Thoofer, James F. Rooney, Lisa Frenkel, K. Rivet Amico, Lameck Chinula, Judith Currier, IMPAACT 2010/VESTED study team and investigators. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2021. 397: 1276-92.

Journal

Lancet

Study

IMPAACT 2010